Remedium Lifecare Ltd
Supha Pharmachem Ltd, formerly Remedium Lifecare, is a pharmaceutical supply-chain trader of APIs, advanced intermediates, KSMs/CRMs and other pharma chemicals for domestic and export markets. It operates through the Indian parent and Singapore subsidiary Remlife Global Pte Ltd and entered CIRP on March 17, 2026. [1]
- Market Cap ₹ 22.0 Cr.
- Current Price ₹ 0.25
- High / Low ₹ 1.34 / 0.23
- Stock P/E 10.4
- Book Value ₹ 1.19
- Dividend Yield 0.00 %
- ROCE %
- ROE 4.85 %
- Face Value ₹ 1.00
Pros
- Stock is trading at 0.21 times its book value
Cons
- Company has low interest coverage ratio.
- Promoter holding is low: 1.13%
- Earnings include an other income of Rs.10.8 Cr.
- Company has high debtors of 695 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Services Services Commercial Services & Supplies Trading & Distributors
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
(S): Standalone figures, shown where consolidated figures are not available.
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2007 (S) | Mar 2015 (S) | Mar 2016 (S) | Mar 2017 (S) | Mar 2018 (S) | Mar 2019 (S) | Mar 2020 (S) | Mar 2021 (S) | Mar 2022 (S) | Mar 2023 (S) | Mar 2024 (S) | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 4 | 1 | 0 | 0 | 3 | 90 | 505 | 510 | 4,040 | 405 | |
| Sales growth | +14% | +85% | -66% | -74% | -54% | +1,706% | +3,015% | +461% | +1% | +692% | ||
| 1 | 2 | 4 | 1 | 0 | 0 | 2 | 89 | 503 | 502 | 4,006 | 404 | |
| Operating Profit | 0 | -0 | -0 | -0 | 0 | -0 | 0 | 1 | 2 | 8 | 34 | 1 |
| OPM % | 3.4% | -8% | -8% | -7% | 0.0% | -44% | 14% | 0.8% | 0.4% | 1.6% | 0.8% | 0.3% |
| 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 21 | 11 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 8 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 7 | 50 | 4 |
| Tax % | 50% | 21% | 0% | 0% | 0% | 100% | 24% | 26% | 29% | 27% | 35% | 51% |
| 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 5 | 33 | 2 | |
| EPS in Rs | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.02 | 0.09 | 0.57 | 0.04 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
(S): Standalone figures, shown where consolidated figures are not available.
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -22% |
| 3 Years: | -76% |
| 1 Year: | -81% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 5% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2007 (S) | Mar 2015 (S) | Mar 2016 (S) | Mar 2017 (S) | Mar 2018 (S) | Mar 2019 (S) | Mar 2020 (S) | Mar 2021 (S) | Mar 2022 (S) | Mar 2023 (S) | Mar 2024 (S) | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 10 | 40 | 88 |
| Reserves | -0 | -1 | -1 | -1 | -1 | -1 | -0 | 0 | 1 | 7 | 33 | 4 | 17 |
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 10 | 0 | 0 | 58 | 1,141 | 1,088 | |
| 1 | 3 | 2 | 0 | 0 | 0 | 1 | 24 | 219 | 1,144 | 1,847 | 535 | 430 | |
| Total Liabilities | 6 | 6 | 5 | 3 | 3 | 4 | 4 | 39 | 224 | 1,154 | 1,948 | 1,720 | 1,623 |
| 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 4 | 4 | 5 | 3 | 3 | 4 | 4 | 38 | 224 | 1,154 | 1,948 | 1,720 | 1,617 | |
| Total Assets | 6 | 6 | 5 | 3 | 3 | 4 | 4 | 39 | 224 | 1,154 | 1,948 | 1,720 | 1,623 |
(S): Standalone figures, shown where consolidated figures are not available.
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2007 (S) | Mar 2015 (S) | Mar 2016 (S) | Mar 2017 (S) | Mar 2018 (S) | Mar 2019 (S) | Mar 2020 (S) | Mar 2021 (S) | Mar 2022 (S) | Mar 2023 (S) | Mar 2024 (S) | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 | -1 | 0 | -0 | -0 | -0 | -10 | 11 | 20 | -74 | -1,135 | ||
| 0 | 1 | 0 | 0 | 1 | -0 | -0 | -0 | -0 | 0 | 0 | ||
| -0 | -0 | 0 | 0 | 0 | 0 | 10 | -11 | -0 | 54 | 1,136 | ||
| Net Cash Flow | -0 | 0 | 0 | -0 | 1 | -0 | -0 | 1 | 20 | -20 | 1 | |
| Free Cash Flow | 0 | 0 | 0 | -0 | -0 | -0 | -10 | 11 | 20 | -74 | -1,135 | |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | -53% | 453% | -78% | 114% | -50% | -1,393% | 641% | 281% | -165% | -90,064% |
(S): Standalone figures, shown where consolidated figures are not available.
Ratios
Consolidated / View Standalone
| Mar 2007 (S) | Mar 2015 (S) | Mar 2016 (S) | Mar 2017 (S) | Mar 2018 (S) | Mar 2019 (S) | Mar 2020 (S) | Mar 2021 (S) | Mar 2022 (S) | Mar 2023 (S) | Mar 2024 (S) | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 120 | 341 | 265 | 596 | 2,117 | 319 | 189 | 96 | 46 | 123 | 83 | 695 |
| Inventory Days | 1,129 | 243 | 78 | 0 | 0 | 5 | 12 | 247 | ||||
| Days Payable | 102 | 438 | 129 | 62 | 65 | 459 | ||||||
| Cash Conversion Cycle | 1,147 | 146 | 214 | 596 | 2,117 | 319 | 189 | 96 | 46 | 67 | 30 | 483 |
| Working Capital Days | 566 | 107 | 200 | 524 | 2,159 | 4,745 | 323 | 54 | 2 | -8 | 4 | 38 |
| ROCE % | 1% | 1% | 0% | 1% | 1% | 11% | 7% | 18% | 103% | 100% |
(S): Standalone figures, shown where consolidated figures are not available.
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| FOB Value of Exports Rs. Lakhs ・Standalone data |
|
|||||||||
| CIF Value of Imports Rs. Lakhs ・Standalone data |
||||||||||
| Number of Permanent Employees (including Directors) count ・Standalone data |
||||||||||
Extracted by Screener AI
Documents
Announcements
-
Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015 Regarding The Order Passed By Hon'Ble National Company Law Appellate Tribunal (NCLAT) Principal Bench, New Delhi
- NCLAT disposed appeal in CIRP, barred CoC voting and immovable property sale till 29 June 2026.
-
Closure of Trading Window
- Trading window closed from 1 July 2026 until 48 hours after Q1 FY2026 results.
-
Intimation Of Change In Insolvency Professional - Appointment Of Resolution Professional (RP) In Place Of Interim Resolution Professional (IRP)
- NCLT approved Raju Mangilal Marshiya as RP for Supha Pharmachem on May 11, 2026.
-
Post- Coc Update
- 1st CoC on 14 Apr 2026 approved RP appointment, expenses, bank operations; directors remain non-cooperative.
-
Corporate Insolvency Resolution Process (CIRP)-List of Creditors
- Supha Pharmachem published creditor list during CIRP; CoC meets 14 April 2026.
Annual reports
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
Entity & consolidation:
The Co's name changed from Remedium Lifecare to Supha Pharmachem effective December 15, 2025.[1]
Its Singapore subsidiary Remlife Global, incorporated on Sep,24, contributed ₹102.48 crore revenue and ₹8.55 crore PAT in Q2 FY26 versus group revenue/PAT of ₹111.06 crore/₹8.62 crore. [2]